Executive Summary
The PARTNER 3 7-year health status update in JACC ends the "patients feel better sooner" argument for TAVR-first in low-risk patients: the early QoL advantage fully disappears by year 3 and stays gone through year 7, with ~60% of patients in both arms alive with excellent KCCQ scores. That finding directly supports the ESC 2025 preference for SAVR under age 70 and complicates the ACC/AHA 2020 shared-decision zone from 65–80. An interrupted time-series of 81,142 TAVR hospitalizations confirms the 2019 low-risk indication expansion drove volume up 134% and mortality down to 0.84% — real gains, paired with persistent racial access gaps. Abbott launched the TREAT TR real-world TriClip study hours before VDyne dosed its first TriNova TTVR pivotal patient — the tricuspid space is now formally a two-front war between repair and replacement, which tightens the case for early referral before RV failure closes the treatment window.
- PARTNER 3 at 7 years: TAVR and SAVR QoL scores converge by year 3 and remain indistinguishable, with ~60% "excellent outcome" in both arms (JACC).
- Post-2019 low-risk expansion: TAVR volume +134%, mortality 1.58%→0.84%, but Black and Hispanic patients still present late and access gains are modest (Cardiology in Review).
- NIS 2016–2022 mitral analysis: Black patients had 49% higher adjusted inpatient mortality after mitral intervention despite receiving more TEER (Cardiology Research).
- [NOTABLE] Early TAVI for asymptomatic severe AS is now formally cost-effective, backing the ESC 2025 Class IIa upgrade (Medscape).
- NCDR analysis: higher TAVR volume correlates with fewer complications but not lower failure-to-rescue rates — technical skill is not the same as bailout capability (ACC).
What to watch: The proposed 2026 CMS TAVR NCD update — covered by TCTMD from NY Valves — will determine whether volume thresholds tighten or loosen in the wake of the failure-to-rescue data.
Aortic Valve (TAVR/TAVI)
Seven-year PARTNER 3 health status data eliminates one of the last standing arguments for TAVR-first in low-risk patients. In the JACC report from Brener, Cohen, Kodali, Hahn, Thourani and colleagues, the 16.2-point KCCQ-OS advantage TAVR held at 1 month shrank to 1.9 points at 2 years and vanished from years 3 through 7 (n=943, mean STS-PROM 1.9%). About 60% of patients in both arms were alive with KCCQ-OS ≥75 and no meaningful decline at seven years. TAVR gets patients back on their feet faster; it does not keep them there better. The ESC 2025 Class I preference for SAVR under age 70 is directly supported by this convergence, and the ACC/AHA 2020 shared-decision zone from 65–80 is harder to defend on patient-preference grounds alone — the early-recovery argument no longer wins durability debates at year 7. Both guidelines agree, however, that durability data beyond 10 years remains unavailable for TAVI, and patients in their late 60s with 15–20-year life expectancy cannot bank on follow-up that does not yet exist.
Parallel evidence adds nuance. An interrupted time-series of 81,142 TAVR hospitalizations confirms the 2019 low-risk expansion drove in-hospital mortality from 1.58% to 0.84% and tripled the low-risk proxy prevalence, with stroke, pacemaker, and vascular complications all improving — real gains, paired with persistent racial access gaps. An Egyptian single-center prospective cohort (N=95) confirms aortic valve and LVOT calcium scores predict PVL, high-grade AV block, and postimplant balloon dilation — small, single-center, exploratory, but a useful reminder that anatomy still trumps operator confidence. A UK five-year TAVI cohort (N=219) found severe PH did not independently increase mortality after TAVI; peripheral vascular disease and low BMI did. The De Ritis (AST/ALT) ratio in PLoS One correlated with 30-day stroke, AKI, and new-onset AFib in >700 patients, but the ≥1.4 threshold was borrowed from prior literature, not derived in this cohort — treat as exploratory only. A JACC Case Reports write-up of catastrophic protamine-induced RV failure post-TAVR, rescued by Impella RP, is a useful reminder that heparin reversal carries real risk in patients with baseline RV dysfunction.
Guideline reference: ACC/AHA 2020 recommends SAVR for patients <65; ESC 2025 raised the SAVR-preferred floor to <70 with TAVI Class I at ≥70 in patients with tricuspid anatomy and transfemoral access.
Mitral Valve (MitraClip, PASCAL, TMVR)
Race is a stronger predictor of who dies after mitral intervention than anatomy, according to the largest US analysis to date. Awad and colleagues in Cardiology Research analyzed 26,456 NIS mitral interventions (2016–2022, 89% TEER) and found Black patients had 49% higher adjusted inpatient mortality (OR 1.49, 95% CI 1.01–2.19) and Asian/Pacific Islander patients had more than double the odds (OR 2.20, 95% CI 1.30–3.72), despite Black patients being younger and more likely to receive TEER. Late presentation was nearly twice as common in Black (24%) and Hispanic (27%) patients versus White (13%). The NIS design cannot capture MR mechanism, LVEF, or COAPT eligibility — the disparity may be driven by disease severity at presentation, hospital selection, or both — but the late-referral pattern is the most probable explanation, and it maps onto known referral barriers in structural heart care.
Neither ACC/AHA 2020 (TEER Class IIa for ventricular SMR) nor ESC 2025 (TEER Class I for ventricular SMR) addresses referral equity. The ESC's aggressive expansion of TEER indications will amplify these disparities if referral bottlenecks are not fixed first. Separately, a Journal of Echocardiography review emphasizes that TEER echocardiographic guidance now requires live multiplanar reconstruction and detailed pre-procedural leaflet morphology assessment — reinforcing that TEER remains an imaging-intensive procedure where operator experience directly affects outcomes. Surgical repair remains the standard for primary MR: ESC 2025 upgraded early repair in asymptomatic patients with 3+ risk factors (AF, SPAP >50 mmHg, LAVI ≥60 mL/m², moderate TR) to Class I; ACC/AHA 2020 still requires >95% repair success and <1% mortality at Class IIa.
Tricuspid Valve (TriClip, TTVR)
Tricuspid therapy became a two-device pivotal race in a single day. Abbott launched TREAT TR, a real-world post-market outcomes study of TriClip, hours after VDyne treated its first patient in the TRIVITA US IDE pivotal trial of the TriNova TTVR system. Repair (TriClip, PASCAL) and replacement (EVOQUE, TriNova, LuX-Valve Plus) will now be tested in overlapping populations simultaneously. The STS/ACC TVT Registry EVOQUE data — 3.1% 30-day mortality, 97.7% mild-or-less TR — has set the real-world benchmark any new device must clear. New pacemaker implantation was 15.9% and bleeding 7.9% in the TVT Registry, meaningfully lower than in the TRISCEND II pivotal, which remains the chief liability of replacement over repair for now.
[NOTABLE] The TRINITY pivotal trial of LuX-Valve Plus vs EVOQUE (N=680) is now recruiting — the first head-to-head TTVR-vs-TTVR pivotal, and the study that will define what second-generation TTVR means competitively.
The surgical counterpoint: ESC 2025 upgraded TV surgery for symptomatic severe primary TR to Class I and for asymptomatic severe primary TR with RV dilation to Class IIa. ACC/AHA 2020 remains at Class IIa and IIb respectively. Both guidelines warn that isolated TV surgery mortality runs 8–20% in older cohorts, driven predominantly by late referral with established RV failure. Transcatheter TR therapy carries ESC 2025 Class IIa (LOE A) for high-risk symptomatic patients without severe RV dysfunction; ACC/AHA 2020 predates the pivotal trial data and does not yet address it. The signal to referring cardiologists is unchanged: evaluate patients before RV fails, regardless of which device ultimately wins.
Surgical vs. Transcatheter Comparisons
PARTNER 3 at seven years is the week's definitive head-to-head signal: TAVR delivers earlier recovery; SAVR catches up by year 3 and remains equivalent through year 7. Combined with durability uncertainty beyond a decade, this reinforces the ESC 2025 age-70 threshold as the more defensible position than the ACC/AHA 2020 age-65 threshold. Patients in their late 60s who will live 15–20 more years cannot rely on transcatheter durability data that extends only to year 10 in the best-followed trials.
The life-cycle assessment in Heart (n=30, single-center) found TF-TAVI generates 38% the carbon footprint of SAVR per case, using 51% less material, 52% less energy, and 97% less water. No patient chooses a valve strategy on kg CO₂-eq. The finding does, however, deflate the soft argument that greater resource intensity signals greater procedural definitiveness, and it flags reusable delivery systems as a legitimate industry target.
Device & Technology
Medtronic recalled thousands of cannulae over leak risk (via CardiovascularBusiness) — a device-quality event that lands as MDT stock continues to underperform peers. Not a valve device, but the reputational drag matters as Medtronic pushes Evolut against SAPIEN.
Regulatory & Policy
TCTMD's third installment on the proposed 2026 CMS TAVR NCD continues to preview a policy that will likely tighten site-volume and outcomes requirements. The NCDR analysis showing higher TAVR volume correlates with fewer complications but not lower failure-to-rescue rates gives CMS a precise evidentiary hook: raising volume floors reduces complications but does not fix bailout capability. Bailout capability is a hospital-systems problem — rapid TEE, backup surgical team, ECMO readiness — not a volume problem. Expect NCD language on rescue infrastructure, not just volume thresholds.
Industry & Market
Edwards outperformed peers on a strong trading day, closing +2.49% at $85.76. Q2 results plus a stronger 2026 sales outlook (SimplyWall.St) reset the narrative, and UBS upgraded EW from Neutral to Buy, target $110. Abbott's TREAT TR launch is a defensive play — with EVOQUE, TriNova, and LuX-Valve Plus all in pivotals, generating real-world TriClip evidence now is what preserves TEER as the first-line tricuspid intervention if TTVR data drift toward higher pacemaker rates and bleeding, as TRISCEND II showed.
Financial Analysis
The Edwards rally reflects a clean read on structural heart tailwinds: PARTNER 3 7-year data, while ambiguous on the TAVR-vs-SAVR debate, is unambiguous that TAVR durability holds in the low-risk cohort — no health-status decline signal through seven years. Combined with early TAVI now demonstrated cost-effective in asymptomatic AS (Medscape), the addressable market keeps expanding upstream. Boston Scientific's -50.78% 6-month drawdown is a stark counterexample of what happens when a device-heavy story loses its narrative — whether the ACURATE neo2 and future mitral programs recover investor confidence is the near-term question. Medtronic's -13.51% underperformance and fresh cannulae recall compound a difficult year for MDT structural heart positioning against EW.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Price: $85.76 (+2.49%), 6-month +5.41%
- Market cap: $49.4B | P/E trailing 49.86, forward 25.41 | Beta 0.85
- 52-week range: $72.30 - $96.29
- Analyst target: $100.96 (26 analysts, Buy)
- Next earnings: 2026-07-23 (EPS est $0.74, Rev est $1.68B)
- Commentary: UBS upgrade to Buy with $110 target and Q2 beat drove the pop. PASCAL and EVOQUE remain the structural heart growth story; TREAT TR from Abbott raises competitive pressure on tricuspid share.
Medtronic (MDT)
- Price: $87.54 (+0.76%), 6-month -13.51%
- Market cap: $112.1B | P/E trailing 23.28, forward 13.65 | Beta 0.58
- 52-week range: $73.31 - $106.33
- Analyst target: $98.44 (25 analysts, Buy)
- Next earnings: 2026-09-01 (EPS est $1.39, Rev est $9.55B)
- Commentary: Cannulae recall adds to a difficult 6 months. Evolut continues to compete effectively in TAVR but the corporate story needs a fresh device catalyst.
Abbott (ABT)
- Price: $108.00 (+0.68%), 6-month +0.14%
- Market cap: $188.1B | P/E trailing 34.95, forward 17.81 | Beta 0.61
- 52-week range: $81.97 - $137.49
- Analyst target: $118.42 (24 analysts, Buy)
- Next earnings: 2026-10-14 (EPS est $1.42, Rev est $12.99B)
- Commentary: TREAT TR launch signals commitment to defending TriClip franchise against TTVR entrants. Structural heart is a smaller slice of ABT than of EW, but it is the fastest-growing.
Boston Scientific (BSX)
- Price: $46.04 (-0.04%), 6-month -50.78%
- Market cap: $68.4B | P/E trailing 19.26, forward 12.4 | Beta 0.58
- 52-week range: $42.20 - $109.50
- Analyst target: $72.31 (29 analysts, Strong Buy)
- Next earnings: 2026-07-29 (EPS est $0.83, Rev est $5.37B)
- Commentary: Analysts remain bullish despite the halving of market cap. ACURATE neo2 and portfolio breadth support the thesis; execution and narrative recovery are the near-term catalysts.
Anteris Technologies (AVR.AX)
- Price: $11.29 (-4.73%), 6-month +27.71%
- Market cap: $1.1B | Forward P/E -5.18 | Beta 0.73
- 52-week range: $5.00 - $15.47
- Analyst target: $13.00 (1 analyst)
- Commentary: DurAVR THV development continues to attract interest as a next-generation TAVR platform. Small-cap volatility appropriate for a pre-pivotal-completion story.
Market outlook: The valve device space is bifurcating cleanly. Edwards is executing on both TAVR expansion (asymptomatic AS, cost-effectiveness data) and tricuspid replacement (EVOQUE real-world data). Boston Scientific is rebuilding trust. Medtronic needs a catalyst. Abbott is defending. The pivotal readouts from TRINITY, TRIVITA, and TREAT TR over the next 24 months will redraw the tricuspid map.
Clinical Trial Updates
Aortic
- NCT07735130 — ARBITAR: Angiotensin Receptor Blocker After TAVR in Severe AS with LV Hypertrophy. Phase 4, N=632, Seoul National University Hospital. Not yet recruiting. Tests whether ARB therapy accelerates LV mass regression post-TAVR — a mechanistic question that matters most in the growing asymptomatic-AS cohort.
- NCT07734025: Crea Aortic Valve Pivotal Study. N=30, Onecrea Medical. Not yet recruiting. Small pivotal for a new TAVR platform — early-stage.
Tricuspid Replacement
- [LANDMARK] NCT07454980 — TRINITY Pivotal: Transvenous TTVR with LuX-Valve Plus vs EVOQUE. N=680, Jenscare Innovation. Recruiting. The first head-to-head TTVR-vs-TTVR pivotal — this trial will shape the competitive landscape more than any single-device study and define the second-generation replacement standard.
- TRIVITA US IDE (VDyne TriNova): First patient dosed 2026-07-29 per company release. US pivotal underway.
Tricuspid Repair
- TREAT TR (Abbott TriClip): Just-launched real-world post-market outcomes study. Complements the TRILUMINATE pivotal data that anchored the ESC 2025 Class IIa transcatheter TR recommendation.
Other
- NCT07695701: Acoramidis CMR/echo study. Phase 4, N=150, BridgeBio. Recruiting. TTR amyloid overlap with severe AS remains a key referral question — this study will inform imaging follow-up on medical therapy.
Social & Conference Highlights
NY Valves 2026 coverage continues to circulate through TCTMD, focused on the CMS NCD debate and TAVR volume standards. The volume-vs-failure-to-rescue finding from the ACC NCDR analysis is the most-discussed structural heart data point of the week.
What's next: Watch for the first TRINITY interim safety readout and the finalized CMS NCD language on TAVR volume and rescue infrastructure — both will land against a backdrop of expanding indications and shrinking QoL differentials between TAVR and SAVR. The next front is whether TTVR replacement can match EVOQUE's real-world 3.1% 30-day mortality while lowering the pacemaker and bleeding burden that has, so far, kept transcatheter TR firmly in Class IIa territory.